Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.73 |
| ▸ | OPRM1 | P35372 | 13/20 | 0.55 |
| ▸ | OPRL1 | P41146 | 12/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.55 |
| ▸ | SLC6A9 | P48067 | 5/20 | 0.53 |
| ▸ | SLC6A5 | Q9Y345 | 5/20 | 0.53 |
| ▸ | PLD2 | O14939 | 2/20 | 0.48 |
| ▸ | PLD1 | Q13393 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL318959 | 0.85 | HSD17B10 (0.73) | HSD17B10OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL5556794 | 0.85 | HSD17B10 (0.73) | HSD17B10OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL11880961 | 0.85 | HSD17B10 (0.73) | HSD17B10OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL11593274 | 0.85 | HSD17B10 (0.73) | HSD17B10OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL219618 | 0.84 | HSD17B10 (1.00) | HSD17B10OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL7587764 | 0.84 | HSD17B10 (1.00) | HSD17B10OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL20187145 | 0.84 | HSD17B10 (0.63) | HSD17B10OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL11595827 | 0.84 | HSD17B10 (0.59) | HSD17B10OPRM1OPRL1OPRK1OPRD1 | |
| Ammonia Solution, Strong SCHEMBL1764035 | 0.83 | HSD17B10 (0.97) | HSD17B10OPRM1OPRL1OPRK1OPRD1 | |
| Hydrochloric Acid SCHEMBL6160546 | 0.83 | HSD17B10 (0.97) | HSD17B10OPRM1OPRL1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11535597-B2 | Photoreactive ligands and uses thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-12-27 | — | — | US | disclosed |
| CN-107849044-B | Triaza-spirodecanones as DDR1 inhibitors | 豪夫迈·罗氏有限公司 | 2021-06-25 | — | — | CN | disclosed |
| EP-3317279-B1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-01-27 | — | — | EP | disclosed |
| US-20200071277-A1 | PHOTOREACTIVE LIGANDS AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2020-03-05 | — | — | US | disclosed |
| US-10435407-B2 | Triaza-spirodecanones as DDR1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-20190169189-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2019-06-06 | — | — | US | disclosed |
| US-10239876-B2 | Triaza-spirodecanones as DDR1 inhibitors | HOFFMAN LA-ROCHE INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180148450-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | HOFFMANN LA-ROCHE INC. (US) | 2018-05-31 | — | — | US | disclosed |
| EP-1931680-B1 | INDOL-3-YL-CARBONYL-AZASPIRO DERIVATIVES AS VASOPRESSIN RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-11-17 | — | — | EP | disclosed |
| US-7790752-B2 | Indol-3-yl-carbonyl-azaspiro derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7189850-B2 | E.g., 1-phenyl-8-(2-phenyl-cyclohexyl)-1,3,8-triaza-spiro[4.5]decan-4-one; activation of N-methylaspartic acid receptors via Glycine (Gly t-1) inhibition; psychoses; analgesics; neurodegenerative and psychological disorders; schizophrenia; cognition activators; antidepressants; Alzheimer's disease | HOFFMANN-LA ROCHE INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189850-B2 | E.g., 1-phenyl-8-(2-phenyl-cyclohexyl)-1,3,8-triaza-spiro[4.5]decan-4-one; activation of N-methylaspartic acid receptors via Glycine (Gly t-1) inhibition; psychoses; analgesics; neurodegenerative and psychological disorders; schizophrenia; cognition activators; antidepressants; Alzheimer's disease | HOFFMANN-LA ROCHE INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189850-B2 | E.g., 1-phenyl-8-(2-phenyl-cyclohexyl)-1,3,8-triaza-spiro[4.5]decan-4-one; activation of N-methylaspartic acid receptors via Glycine (Gly t-1) inhibition; psychoses; analgesics; neurodegenerative and psychological disorders; schizophrenia; cognition activators; antidepressants; Alzheimer's disease | HOFFMANN-LA ROCHE INC. (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1678177-A1 | TRIAZA-SPIROPIPERIDINE DERIVATIVES FOR USE AS GLYT-1 INHIBITORS IN THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-07-12 | — | — | EP | disclosed |
| US-20050107373-A1 | E.g., 1-phenyl-8-(2-phenyl-cyclohexyl)-1,3,8-triaza-spiro[4.5]decan-4-one; activation of N-methylaspartic acid receptors via Glycine (Gly t-1) inhibition; psychoses; analgesics; neurodegenerative and psychological disorders; schizophrenia; cognition activators; antidepressants; Alzheimer's disease | F. HOFFMANN-LA ROCHE AG (CH) | 2005-05-19 | — | — | US | disclosed |
| WO-2005040166-A1 | TRIAZA-SPIROPIPERIDINE DERIVATIVES FOR USE AS GLYT-1 INHIBITORS IN THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-05-06 | — | — | WO | disclosed |
| EP-0273168-A1 | Triazaspirodecanylmethylindolone derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1988-07-06 | — | — | EP | disclosed |
| US-4707484-A | Substituted piperidinomethylindolone and cyclopent(b)indolone derivatives | HOFFMANN-LA ROCHE INC. (US) | 1987-11-17 | — | — | US | disclosed |
| US-4076821-A | 4,4-Diphenylcycloalkylpiperidines and psychotropic compositions thereof | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JA) | 1978-02-28 | — | — | US | disclosed |
| US-3996363-A | ANTIDEPRESSANT, ANTIINFLAMMATORY | E. R. SQUIBB & SONS, INC. (US) | 1976-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11535597-B2 | Photoreactive ligands and uses thereof | CLTB, CRYAB, CRYAA | HSD17B10 2979/4885OPRM1 3406/4885OPRL1 644/4885 |
| US-20190169189-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | DDR1, DDR2, DDRGK1 | HSD17B10 2768/4885OPRM1 4280/4885OPRL1 2399/4885 |
| US-20180148450-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | DDR1, DDR2, DDRGK1 | HSD17B10 2768/4885OPRM1 4280/4885OPRL1 2399/4885 |
| US-10435407-B2 | Triaza-spirodecanones as DDR1 inhibitors | DDR1, DDR2, DDRGK1 | HSD17B10 2768/4885OPRM1 4280/4885OPRL1 2399/4885 |
| US-20050107373-A1 | E.g., 1-phenyl-8-(2-phenyl-cyclohexyl)-1,3,8-triaza-spiro[4.5]decan-4-one; activation of N-methylaspartic acid receptors via Glycine (Gly t-1) inhibition; psychoses; analgesics; neurodegenerative and psychological disorders; schizophrenia; cognition activators; antidepressants; Alzheimer's disease | GRIN1, GRIN2A, GRM1 | HSD17B10 2689/4885OPRM1 70/4885OPRL1 8/4885 |
| US-20200071277-A1 | PHOTOREACTIVE LIGANDS AND USES THEREOF | CLTB, CRYAB, CRYAA | HSD17B10 2979/4885OPRM1 3406/4885OPRL1 644/4885 |
| US-10239876-B2 | Triaza-spirodecanones as DDR1 inhibitors | DDR1, DDR2, DDRGK1 | HSD17B10 2768/4885OPRM1 4280/4885OPRL1 2399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.